Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #1
$599.00
Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #1
$599.00
A US key opinion leader (KOL) discusses key late-phase pipeline and marketed drugs for major depressive disorder and highlights the significance of unique mechanisms of action in the market.
Publisher: Biomedtracker
Published:
02 October 2018
Number of pages:
15
Formats:
PDF
Report code:
TL #10133
- Highlights
- Description
Highlights
- “I kind of perceive [ALKS 5461] in my mind like the use of ketamine, obviously there is a wrong way to use it, and there is a right way to use it, so there is something in the NMDA receptor that has abuse potential, it also has treatment or salvaging potential, and I think the same way about the pathway that the ALKS agent has, there is a wrong way to approach that mechanism of action, and there is a right way to approach that mechanism of action.”
Drug Coverage
- Abilify
- ALKS 5461
- BuSpar
- Cymbalta
- Esketamine
- Fetzima
- ketamine
- Lexapro
- Pristiq
- Prozac
- Rapastinel
- Rexulti
- SAGE-217
- Seroquel
- Travivo
- Trintellix
- Viibryd
- Vraylar
- Zulresso
Overview
A US key opinion leader (KOL) discusses key late-phase pipeline and marketed drugs for major depressive disorder and highlights the significance of unique mechanisms of action in the market.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #2 
Sign up to the